Early diagnosis of COPD, chronic obstructive pulmonary disease, increases the quality of life of the patient and the efficacy ...

For patients with chronic obstructive pulmonary disorder (COPD), long-term inhaled corticosteroid (ICS) treatment is ...

Patients with COPD plus a depression/anxiety disorder had poorer scores related to disease burden and health-related quality of life, according to data published in Chronic Obstructive Pulmonary ...

Background and goal: Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended as first-line treatment unless patients have asthma ...

Medically reviewed by Sanja Jelic, MD Asthma and chronic obstructive pulmonary disease (COPD) are chronic respiratory (lung) ...

The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

but the findings suggest benefits with delandistrogene moxeparvovec treatment. Notably, NSAA score increases and time function test improvements that were not shown on the poster were greater in ...

Stimulants are the most common ADHD medications, but they don’t work for everyone. Nonstimulants have fewer side effects but take longer to work. If you have attention deficit hyperactivity ...

treatment, and care. Sharon Hesterlee, PhD: Definitely the networking. I think the presentations are excellent, of course, but I think it's being able to talk to people at poster sessions and ...